01:28 , Oct 19, 2012 |  BC Extra  |  Financial News

CytRx raises $20 million in follow-on

CytRx Corp. (NASDAQ:CYTR) raised $20 million through the sale of 8 million shares at $2.50 in a follow-on underwritten by Aegis Capital. CytRx was off $0.61 (20%) $2.50 on Thursday. CytRx's pipeline includes three clinical...
00:31 , Jul 28, 2011 |  BC Extra  |  Financial News

CytRx prices follow-on

CytRx Corp. (NASDAQ:CYTR) raised $20.4 million through the sale of 39.2 million shares and warrants at a combined price of $0.52 in a follow-on underwritten by Cowen and Roth Capital Partners. Each share was priced...
00:06 , Jul 27, 2011 |  BC Extra  |  Financial News

CytRx planning follow-on

CytRx Corp. (NASDAQ:CYTR) said late Tuesday it is planning a follow-on underwritten by Cowen and Roth Capital Partners. Details were not disclosed. CytRx was off $0.05 to $0.64 on the day. CytRx's pipeline includes three...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

Bafetinib: Preliminary Phase II data

Preliminary data from the ongoing, U.S. Phase II ENABLE trial in 11 evaluable patients with relapsed or refractory B cell CLL who failed previous therapy showed that twice-daily 240 mg oral bafetinib produced 2 cases...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Clinical News

CytRx, Nippon Shinyaku preclinical data

In monocytes isolated from the peripheral blood and bone marrow of patients with multiple myeloma (MM), bafetinib significantly suppressed the activity of osteoclasts and inhibited bone reabsorption in a dose-dependent manner. Bafetinib is in Phase...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

CytRx, RXi Pharmaceuticals deal

CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif.   RXi Pharmaceuticals Corp. (NASDAW:RXII), Worcester, Mass.   Business: Cancer   CytRx divested its 17% stake in RXi for about $7 million to the open market. CytRx plans to...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

Bafetinib: Pilot trial started

CytRx began an open-label, U.S. pilot trial in 6-8 patients with recurrent primary brain cancer or recurrent brain metastases to evaluate twice-daily oral bafetinib following intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. CytRx has...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

Bafetinib: Phase II started

CytRx began the open-label, international Phase II PROACT trial to evaluate oral bafetinib given twice daily in about 50 metastatic HRPC patients who failed first-line chemotherapy. CytRx has rights to the compound outside Japan from...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

Bafetinib: Phase II started

CytRx began the Phase II ENABLE trial to evaluate twice-daily oral bafetinib in high-risk patients who have previously failed treatment with first-line agents. CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif.   Nippon Shinyaku Co. Ltd. (Tokyo:4516;...
07:00 , Mar 22, 2010 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes...